What are the side effects of Pemvidutide?
The most commonly reported Pemvidutide side effects are nausea (titration steps), diarrhea, mild HR increase (glucagon effect). Most are mild and tend to be dose dependent. It is generally avoided with mTC / MEN-2 history. Human clinical evidence for Pemvidutide is limited, so this reflects reported and observed effects, not a complete safety profile.
Reported Pemvidutide side effects
- Nausea (titration steps)
- Diarrhea
- Mild HR increase (glucagon effect)
- Fatigue
Who should avoid it
- MTC / MEN-2 history
- Pancreatitis history
- Severe cardiovascular disease
- Pregnancy / nursing
Bloodwork worth tracking
- Lipid panel
- ALT/AST
- Liver imaging if NASH context
- A1C
References
- Pemvidutide for the treatment of NAFLD/NASH, Phase 1b — Altimmune Phase 1b readout, 2023
- Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study — Harrison SA et al., Journal of Hepatology, 2025
- Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis — Noureddin M et al., The Lancet, 2025
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Pemvidutide
Last updated 2026-06-06.